Prostate Cancer - Results from #400

Oligometastatic Prostate Cancer: Current Status and Future Challenges. November 3, 2022

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA. November 3, 2022

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. November 3, 2022

Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update. November 2, 2022

Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study. November 2, 2022

Transurethral Vapor Ablation in Patients with Intermediate Risk Localized Prostate Cancer. November 2, 2022

Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer. November 2, 2022

Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. November 2, 2022

Quantifying Radiosensitization of PSMA-Targeted Gold Nanoparticles on Prostate Cancer Cells at Megavoltage Radiation Energies by Monte Carlo Simulation and Local Effect Model. November 2, 2022

Prognostic value of tumor volume assessment on PSMA PET after 177Lu-PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0. November 2, 2022

The 17-Gene Genomic Prostate Score® Test is Prognostic for Outcomes after Primary External Beam Radiation Therapy in Men with Clinically Localized Prostate Cancer. November 1, 2022

Molecular Mechanisms of Castrate-Resistant Prostate Cancer. November 1, 2022

Impact of choosing wisely on imaging in men with newly diagnosed prostate cancer. November 1, 2022

Testosterone Therapy and Prostate Cancer: Incorporating Low-Level Evidence into Practical Recommendations. November 1, 2022

The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. November 1, 2022

A Systematic Review to Evaluate Patient-Reported Outcome Measures (PROMs) for Metastatic Prostate Cancer According to the COnsensus-Based Standard for the Selection of Health Measurement INstruments (COSMIN) Methodology. November 1, 2022

Patterns of metastases progression- The linear parallel ratio. November 1, 2022

Movember Launches First of Its Kind Clinical Guidelines Driving Excellence in Sexual Health Care in Prostate Cancer October 31, 2022

Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program. October 31, 2022

Intermediate-term oncological outcomes after a negative endorectal coil multiparametric MRI of the prostate in patients without biopsy proven prostate cancer. October 31, 2022

Page 21 of 1277

email news signup